ACAD ACADIA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1070494 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.8%
TTM net income YoY38.7%
TTM EPS YoY36.8%
Revenue 3-yr CAGR23.9%
Net income 3-yr CAGR—
Margins
Gross margin90.5%
Operating margin10.2%
Net margin30.1%
FCF margin6.8%
EBITDA margin10.3%
Returns
ROE31.4%
ROA23.2%
ROIC (approx.)14.2%
Asset turnover0.77x
Leverage & solvency
Liabilities / assets22.7%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.27x
Accruals ratio16.9%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.07B | $957.80M | $726.44M | $517.24M | $484.14M |
| Cost of revenue | $89.00M | $81.84M | $41.64M | $10.17M | $19.14M |
| Gross profit | $982.51M | $875.96M | $684.80M | $507.07M | $473.30M |
| R&D expense | $328.80M | $303.25M | $351.62M | $361.57M | $239.41M |
| SG&A expense | $548.89M | $488.43M | $406.56M | $369.09M | $396.03M |
| Operating income | $104.81M | $230.79M | -$73.38M | -$223.60M | -$170.44M |
| Pretax income | $138.90M | $258.07M | -$51.04M | -$213.44M | -$167.52M |
| Income tax | -$252.10M | $31.62M | $10.25M | $2.53M | $351,000 |
| Net income | $391.00M | $226.45M | -$61.29M | -$215.97M | -$167.87M |
| EBITDA | $105.68M | $231.71M | -$71.92M | -$221.57M | -$168.20M |
| EPS (basic) | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 |
| EPS (diluted) | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 |
| Weighted avg. shares (diluted) | 169.92M | 166.36M | 163.82M | 161.68M | 160,493 |
| Balance sheet | |||||
| Cash & equivalents | $177.69M | $319.59M | $188.66M | $114.85M | $147.44M |
| Short-term investments | $641.99M | $436.40M | $250.21M | $301.98M | $373.27M |
| Receivables | $121.46M | $98.74M | $98.27M | $62.20M | $64.37M |
| Inventory | $111.37M | $91.69M | $40.45M | $11.56M | $14.10M |
| Current assets | $1.06B | $938.32M | $616.12M | $507.94M | $617.82M |
| PP&E, net | $7.51M | $4.21M | $4.61M | $6.02M | $8.05M |
| Intangibles | $108.89M | $119.78M | $65.49M | $0 | $0 |
| Total assets | $1.56B | $1.19B | $748.96M | $587.81M | $700.12M |
| Current liabilities | $277.11M | $394.87M | $254.25M | $125.63M | $96.07M |
| Total liabilities | $336.81M | $454.96M | $317.20M | $187.40M | $159.23M |
| Shareholders' equity | $1.23B | $732.79M | $431.75M | $400.41M | $540.89M |
| Shares outstanding | 170.31M | 166.71M | 164.65M | 162.06M | 161.01M |
| Cash flow statement | |||||
| Operating cash flow | $109.84M | $157.72M | $16.70M | -$114.03M | -$125.66M |
| Capital expenditure | $4.69M | $523,000 | $50,000 | $0 | $1.12M |
| Free cash flow | $105.15M | $157.20M | $16.65M | -$114.03M | -$126.78M |
| Investing cash flow | -$302.56M | -$30.54M | $32.00M | $73.24M | -$71.10M |
| Financing cash flow | $49.88M | $6.84M | $25.13M | $8.20M | $18.16M |
| Depreciation & amortization | $871,000 | $920,000 | $1.46M | $2.03M | $2.24M |
| Stock-based compensation | $52.13M | $67.05M | $66.42M | $68.20M | $63.62M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.